Dan Schultz
Director, CDRH
- Главная
- Разное
- Дизайн
- Бизнес и предпринимательство
- Аналитика
- Образование
- Развлечения
- Красота и здоровье
- Финансы
- Государство
- Путешествия
- Спорт
- Недвижимость
- Армия
- Графика
- Культурология
- Еда и кулинария
- Лингвистика
- Английский язык
- Астрономия
- Алгебра
- Биология
- География
- Детские презентации
- Информатика
- История
- Литература
- Маркетинг
- Математика
- Медицина
- Менеджмент
- Музыка
- МХК
- Немецкий язык
- ОБЖ
- Обществознание
- Окружающий мир
- Педагогика
- Русский язык
- Технология
- Физика
- Философия
- Химия
- Шаблоны, картинки для презентаций
- Экология
- Экономика
- Юриспруденция
Critical Path Research: Getting New Technology from Bench to Bedside A Device. Perspective FDA Science Board November 5, 2004 презентация
Содержание
- 1. Critical Path Research: Getting New Technology from Bench to Bedside A Device. Perspective FDA Science Board November 5, 2004
- 2. Role of FDA Establish reasonable assurance of
- 3. What is a “Device”?
- 4. A Computer You Can Swallow
- 5. A Computer That Helps You Hear
- 6. Devices that Measure Glucose Levels and Deliver Insulin to “Communicate”
- 7. Miniaturized Electrical Stimulators Pacemakers
- 8. Drug-Eluting Stents Components Stent Platform & Delivery System Carrier(s) Drug
- 9. New Technology Important Trends
- 10. CDRH Vision – Total Product Life Cycle
- 11. Devices are Different Drugs Pure molecules
- 12. Critical Path is Different for Devices Device
- 13. Dun & Bradstreet Medical Device Firm Data
- 14. Sales Volume Growth (Billions of Dollars) Note: No Economic Adjustment to Dollar Value
- 15. Device Industry Continues to Grow in FY
- 16. Innovative Science-based Strategies at Work Leveraging Breast
- 17. Days *Based on all 510(k)s (1,644)
- 18. Original PMA Milestones: 2-cycle Scenario Filing Rev
- 19. Original PMA Milestones: 1-cycle Scenario Filing Review
- 20. The rest of the story…
- 21. Drug-coated stents may face additional FDA scrutiny
- 22. Goal: Prioritize Actions on GMP Risks Correlating
- 23. Postmarket Questions of Interest Long Term Safety
- 24. Achieving Pre/Postmarket Balance
- 25. Why Balance Works Speeds Product to Market
- 26. Postmarket Studies - Present Ill-Conceived Not Initiated Not Completed Not Tracked Not Enforced
- 27. Postmarket Studies - Future Better Designs
- 28. Life Sciences Laboratory Awards 2004, GSA Construction
- 29. Critical Path Projects Being Developed Establishing a
- 30. Critical Path Projects Being Developed Establishing agreed
- 31. Summary Steady progress towards meeting review performance
- 32. CDRH Vision – Total Product Life Cycle
Слайд 1Critical Path Research: Getting New Technology from Bench to Bedside A
Device Perspective
FDA Science Board
November 5, 2004
Слайд 2Role of FDA
Establish reasonable assurance of the safety and effectiveness of
medical devices marketed in the U.S.
Слайд 9New Technology
Important Trends
Miniaturization
Intelligent Devices
Designed for Consumer Use
Minimally invasive
Biotechnology
Revolution
Genomics, Proteomics
Biological Medical Devices
New Materials
Combination Products
Disruptive Technologies
That change how we do business
That change how medical devices deliver value
Genomics, Proteomics
Biological Medical Devices
New Materials
Combination Products
Disruptive Technologies
That change how we do business
That change how medical devices deliver value
Слайд 11Devices are Different
Drugs
Pure molecules
Toxicology
Short half-life
Long market life
Drug interactions
Wrong Drug /
Dose
Clinically studied
Good Manufacturing Practices (cGMP)
Clinically studied
Good Manufacturing Practices (cGMP)
Devices
Complex components
Biocompatibility
Durable Equipment
Rapid product cycles
Malfunction
User Error
Bench studied
Quality Systems
(ISO 9000)
Слайд 12Critical Path is Different for Devices
Device Regulation
Least Burdensome Provision of FDAMA
Quality
Systems and Design Controls
Device Innovation Process
Biocompatibility
Iterative Process
User learning curve
Performance and durability
Device Industry is Represented by Small Manufacturers
Device Innovation Process
Biocompatibility
Iterative Process
User learning curve
Performance and durability
Device Industry is Represented by Small Manufacturers
Слайд 13Dun & Bradstreet Medical Device Firm Data
Medical Device Industry Growth
Number of
Manufacturers by Year
Слайд 15Device Industry Continues to Grow in FY 04
Dun and Bradstreet FY
04 data shows the device industry grew from 13,579 to 14,937 firms with about $320 billion in sales.
Innovation is alive and well!
20% annual turnover in individual device firms.
FDA-industry interaction is more important than ever. FDA needs to keep guidances and reviewers up to date.
Innovation is alive and well!
20% annual turnover in individual device firms.
FDA-industry interaction is more important than ever. FDA needs to keep guidances and reviewers up to date.
Слайд 16Innovative Science-based Strategies at Work
Leveraging
Breast Cancer (DMIST): Screening and Digital Mammography
Medical
Device Fellowship Program
Objective Performance Criteria
Heart valves
Hip implants
Novel Trial Designs
Bayesian Statistics
ROC Curves
Guidance Development
Objective Performance Criteria
Heart valves
Hip implants
Novel Trial Designs
Bayesian Statistics
ROC Curves
Guidance Development
Слайд 17
Days
*Based on all 510(k)s (1,644) with SE decisions during FY 2002
that were for Class II devices eligible for third party review, excluding special and 3rd party 510(k)s
106
140
(n = 1,021)
(n = 623)
Comparison of 510(k) Average Review Times
for Devices With and Without Guidance*
E Rechen, 5/03
Слайд 18Original PMA Milestones:
2-cycle Scenario
Filing Rev
Scientific Review
Panel Planning
Closeout Review
PMA Received
Panel Go/NoGo
Panel Meeting
Filing
Letter
Final Decision
320 days
Major
Def.
Letter
Scientific Review
Clock Stops
Status Letter
Interactive
Review
Consults Complete
Слайд 19Original PMA Milestones:
1-cycle Scenario
Filing Review
Scientific Review
Panel Planning
Closeout Review
PMA Received
Panel
Go/No Go
Panel
Meeting
Filing Letter
Final Decision
180 days
Status
Letter
Consults Complete
Interactive Review
Слайд 21Drug-coated stents may face additional FDA scrutiny
FDA Advises Physicians of Adverse
Events Associated with Cordis Cypher Coronary Stents
Слайд 22Goal: Prioritize Actions on GMP Risks Correlating to Patient Risks
RISK ?
Processes Inspection Risk
RISK ?
Quality (Patient) Factors
GMP
Patient
Слайд 23Postmarket Questions of Interest
Long Term Safety
Performance in Community Practice
Change in User
Setting
Rare/Unexpected Events
Rates of Anticipated Adverse Events
Human Factors Issues – Use Error
Off-Label Use
Rare/Unexpected Events
Rates of Anticipated Adverse Events
Human Factors Issues – Use Error
Off-Label Use
Слайд 25Why Balance Works
Speeds Product to Market by Moving Some Premarket Requirements
to Postmarket
Offers Added Assurance to FDA and Advisory Panel
Free Up ODE Staff for Premarket Review
Generates Data for Next Generation
Generates Data for Enhanced Labeling
Offers Added Assurance to FDA and Advisory Panel
Free Up ODE Staff for Premarket Review
Generates Data for Next Generation
Generates Data for Enhanced Labeling
Слайд 27Postmarket Studies - Future
Better Designs
Standardized Reporting System
Better Tracking
Make Status of
Studies Public
Слайд 28Life Sciences Laboratory
Awards
2004, GSA Construction Excellence, Projects Over
$25 Million
2004, Washington
Building Council, Craftsmanship Award (Mechanical / HVAC-Sheet Metal, Mechanical / Plumbing, Mechanical / HVAC-Piping)
Слайд 29Critical Path Projects Being Developed
Establishing a pedigreed and credentialed blood panel
that could be used for assessing the sensitivity/specificity of new hepatitis assays
Developing computer models of human physiology that allow testing and soft failure of peripheral vascular stents before animal and human studies are ever considered
Developing a clear regulatory path with consensus from the Obstetrics community for intrapartum fetal diagnostic devices
Developing computer models of human physiology that allow testing and soft failure of peripheral vascular stents before animal and human studies are ever considered
Developing a clear regulatory path with consensus from the Obstetrics community for intrapartum fetal diagnostic devices
Слайд 30Critical Path Projects Being Developed
Establishing agreed pathways for the statistical validation
of surrogate markers
Working with Medical Specialty Organizations to develop practice guidelines for appropriate monitoring of permanently implanted devices
Obtaining consensus on the extent of neurotoxicity testing for neural tissue contacting materials
Working with Medical Specialty Organizations to develop practice guidelines for appropriate monitoring of permanently implanted devices
Obtaining consensus on the extent of neurotoxicity testing for neural tissue contacting materials
Слайд 31Summary
Steady progress towards meeting review performance goals and TPLC strategic goals
Success is achievable but highly resource-intensive
CDRH continues to seek innovative methods and partnerships for evaluating new technology based on sound science in a least burdensome manner
Critical path will further our existing efforts to achieve the right regulatory balance and ensure the safety and effectiveness of medical devices
